S2-E57.1 - 2021 TLMdX from AASLD: Putting a "Big, Fat Dent" in NAFLD and NASH

Send us Fan MailManal Abdelmalek, Jörn Schattenberg and Ian Rowe join regulars Stephen Harrison, Louise Campbell and Roger Green to recap NAFLD and NASH-related insights from the 2021 TLMdX, the AASLD annual liver meeting. This conversation focuses on what we have learned about NITs and clinical development testing that will, in the words of Stephen Harrison, "put a big, fat dent in Fatty Liver disease."The conversation starts with the group congratulating Manal Abdelmalek on her wrap-up NAFLD talk at the 2021 TLMdX. From there, the group focuses on the shortcomings of using biopsy as the clinical trial gold standard and how strategic clinical trial design and interpretation of existing NIT data can build a bridge from biopsy through MRE/biopsy correlations to a total NIT future.